Anthony R. Mato

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster, Jakub Svoboda, Elise A. Chong et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text

Life Sciences, Hematology, Immunology +17

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter et al. · Blood · 2013 · 590 citations · Full text

Medicine, Hematology, Immunology +13

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 466 citations

Medicine, Oncology, Hematologic Oncology +9

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Immunology, Pharmacotherapy +12

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 378 citations · Full text

Life Sciences, Hematology, Immunology +12